Senate bill proposes tax exemption for clinical trial participants

A bill introduced in the Senate, titled the Harley Jacobsen Clinical Trial Participant Income Exemption Act of 2026, was read twice and referred to the Committee on Finance. The legislation would amend the Internal Revenue Code to exclude certain income received by individuals who participate in clinical trials from their gross income for federal tax purposes.

Why it matters: This is a targeted tax policy change rather than a broad regulatory shift. It aims to prevent people from owing taxes on compensation they receive for participating in medical research studies. While the impact is limited to a specific group of taxpayers, it addresses a common complaint that trial participation payments are treated as taxable income despite often compensating for time and discomfort rather than labor.

Who it affects

• Individuals who participate in clinical trials and currently report compensation as taxable income

---

The official source is Congress.gov, and readers should check the original bill text for specific definitions of eligible income and trial types before relying on this summary.

Agency: Senate
Source: Congress.gov — read the official document